Clorox vs. Kimberly-Clark: Which Household Staples Dividend Is Safer

Clorox vs. Kimberly-Clark: Which Household Staples Dividend Is Safer

Chris Lange

Mon, September 21, 2026 at 4:19 PM GMT+3 5 min read

• KMB -0.52%
• CLX +0.08%

Quick Read

• Clorox (CLX) CFO Luc Bellet called the 5.86%-yielding dividend "a bit elevated," while Kimberly-Clark (KMB) covers its payout with nearly $1B of cash flow headroom.

• KMB's 54-year consecutive dividend raise streak and international segment growth make it the safer income pick despite CLX's higher nominal yield.

• Just released. Our analysts combed the entire stock market and named the ten best stocks to buy right now, and Kimberly-Clark didn't make the cut. Enter your email to see the names that beat KMB. The report is free. Enter your email and see if any of your stocks made the cut.

For a retiree weighing Clorox (NYSE:CLX) against Kimberly-Clark (NASDAQ:KMB), the question comes down to which of these two household-staples dividends is genuinely safer to own right now. Both are aristocrats. Only one is built to keep raising the check without stress.

Round 1: Current Yield and Raw Income

Clorox delivers the fatter headline number. At $83.48, the stock carries a trailing yield of 5.86% on an annualized forward payout of $5, following the latest raise to $1.25 quarterly declared on July 31, 2026. Kimberly-Clark pays $1.28 quarterly, an annualized $5.12, for a yield of 5.18%.

Clorox wins the income round. On $50,000 invested, the yield gap is real cash. But the gap exists partly because Clorox shares have dropped 29.56% over the past year and 22.63% in the last month alone. High yield in staples is often the market pricing risk, not generosity.

Free Report, Just Released

Why Didn't KMB Make The Top 10 List?

24/7 Wall St has helped investors make money for over two decades, and our top analysts just finished ranking the definitive Top 10 Stocks To Buy Now. Not the ten biggest companies. Not the ten everyone is arguing about. The ten best stocks to buy right now.

And KMB didn't make the cut!

The report is free, and you can see why we think each stock is a top investment today.

Enter Your Email and See the Ten →

Round 2: Dividend Safety (The Round That Decides It)

This is where the comparison stops being close. Clorox generated fiscal-year 2026 operating cash flow of $612 million against a dividend payout of $602 million. After $207 million of capex, free cash flow does not cover the dividend. CFO Luc Bellet acknowledged the pressure on the August 3, 2026 call, saying the current payout is "a bit elevated" and framing it as "more transitory as we rebuild our gross margin and not something structural." The balance sheet is thinner still: shareholders equity ended the fiscal year at just $252 million against total liabilities of $7.542 billion, with GOJO integration adding leverage and approximately $210 million of fiscal 2027 interest expense.

Kimberly-Clark is not close to that strain. Full-year 2025 operating cash flow of $2.777 billion covered a dividend payout of $1.66 billion with room to spare, even after $1.138 billion of capex and buybacks. Shareholders equity stood at $1.874 billion, and Q2 2026 delivered productivity of 6.4% and adjusted gross margin expansion of 190 bps to 38.8%. Yes, the pending $48.7 billion Kenvue acquisition brings integration risk, and China Huggies disinformation is a real 200 basis point second-half drag. But coverage is not the problem.

Kimberly-Clark wins decisively.

Round 3: Pace and Consistency of Dividend Growth

The verified histories tell a clear story: both raise slowly. Clorox went from $1.24 to $1.25 quarterly this cycle. Kimberly-Clark stepped from $1.26 to $1.28, extending its increase streak to 54 consecutive years, one of the longest on the market. Clorox management said on the call the dividend has "increased annually for a decade" and expects that to continue, but the streak and the coverage cushion behind it are both shorter.

Kimberly-Clark wins on consistency. Both lose to inflation on pace.

Structural Pressures That Reach the Payout

Private-label diaper entrants are pressing Kimberly-Clark's North American Huggies franchise, and management flagged approximately $150 million of second-half input-cost headwinds, mostly oil-linked. Clorox faces a heavier version of the same problem: fiscal 2027 inflation projected above $200 million, more than double its historical $75 to $100 million range. Retailer concentration cuts both ways, but Kimberly-Clark's international personal-care segment grew 4.0% in Q2, offering geographic ballast Clorox lacks.

The Verdict

Kimberly-Clark is the safer household-staples dividend for a retirement-focused investor. The payout is covered by free cash flow with real headroom, the balance sheet carries genuine equity, and the 54-year raise streak is backed by durable international exposure. Clorox offers a bigger yield today, but that yield exists because the market is pricing GOJO integration risk, thin equity, and a payout ratio management itself calls elevated. Take the coverage over the coupon. KMB wins.

Got $1,000? Before You Buy KMB, Read This

If you have cash sitting in your account right now, give this two minutes. After more than two decades of helping investors beat the market, our top analysts at 24/7 Wall St. put together a definitive report on the Top 10 Stocks To Buy Today. And KMB wasn't one of them.

They combed the entire market. It's not 10 ideas, not 10 stocks everyone is talking about, it's what their research points to as the 10 best stocks to buy right now, and it's free. Read more here and see which stocks made the list -->>

Contact editorial@247wallst.com for any questions or corrections.